01465nas a2200265   4500000000100000008004100001653001200042653001700054653001200071653003300083653001200116653002200128653001300150100001500163700001500178700001200193700001200205700001100217700001300228245014100241856008200382300000800464490000600472520072100478       2017                            d10aVaccine10aTuberculosis10aMyeloma10aMycobacterium indicus pranii10aleprosy10aAno-genital warts10aAdjuvant1 aTalwar G P1 aZaheer S A1 aGupta S1 aNandi D1 aHada R1 aGupta JC00aMaking of an immuno therapeutic cum immuno prophylactic vaccine against leprosy endowed with multiple properties and useful applications  uhttp://www.e-discoverypublication.com/wp-content/uploads/2017/09/JMD17029.pdf  a1-80 v23 a<p>Reviewed briefly is the development of a unique vaccine against leprosy based on an autoclaved cultivable saprophytic mycobacteria, Mycobacterium indicus pranii (MIP, earlier coded as Mw). MiP is approved by the Drugs Controller General of India and by USFDA. It is transferred to industry and is available to the public. Besides leprosy, MIP is in use as a potent adjuvant enhancing substantially antibody response to a potential Birth Control vaccine against hCG. MIP has both preventive and therapeutic actions against SP2/O myelomas in mice. It cures marvelously ugly warts on feet and in ano-genital regions by intralesional therapies. It has protective and therapeutic properties against tuberculosis.</p>